10 December 2020
Swissmedic is Examining Janssen’s COVID-19 Vaccine
The pharmaceutical company Janssen-Cilag, which is part of the Johnson & Johnson Group, submitted an application to Swissmedic to have its vaccine candidate Ad26.COV2.S authorised. Swissmedic is examining Janssen’s COVID-19 vaccine in a rolling submission procedure.
For further information, see here.
More News
-
-
Swissmedic: New strategic Approach to minimizing Animal Testing in the Development of Medicinal Products
-
Swissmedic: The new Pharmacopoea Helvetica 13
-
European Medicines Agency: New oral GLP-1 Medicine for Weight Management and Type 2 Diabetes
-
FOPH: Capital Income of Health Insurers for Premium Reduction – current voluntary System deemed sufficient
-
Swissmedic: Haemovigilance Annual Report 2025
-
Decision C-6534/2024 of 13 October 2026
-
Swissmedic: GMP Compliance by foreign Manufacturers - Simplifications for Industry and Clarification of unresolved Issues
-
European Medicines Agency: Clinical Trial Applications Advice Pilot becomes permanent
-
Swissmedic: Revision of the Guidance document Authorisation Biosimilar